Korean J Fam Med.  2010 Mar;31(3):171-181. 10.4082/kjfm.2010.31.3.171.

The Comparison of Guidelines for Management of Dyslipidemia and the Appropriateness of Them in Korea

• Cho YG
• Song HJ
• Park BJ
• NECA-9 Lipid Lowering Agents Research Group

• KMID: 1492690
• DOI: http://doi.org/10.4082/kjfm.2010.31.3.171

Abstract

There have been accumulating evidences that dyslipidemia is a major risk factor of cardiovascular disease (CVD) and improvement in lipid profile can reduce the incidence of CVD. Guidelines for management of dyslipidemia have been developed by major organizations in several contries including the United States. In Korea, a guideline was also published by the Korean Society of Lipidology and Atherosclerosis. However, This guideline was not based on evidences in Korea, but was made by a consensus of experts using a pre-developed guideline as a reference. For clinical application for Korean of guidelines developed in different nations, the disease epidemiology and medical environment in Korea should be considered. In this article, we reviewed whether guidelines for management of dyslipidemia are applicable in Korean context.

Keyword

Dyslipidemia; Guideline; Cardiovascular Disease; Epidemiology; Lipid-Lowering Agent; Statin

MeSH Terms

Atherosclerosis
Cardiovascular Diseases
Consensus
Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Incidence
Korea
Risk Factors
United States
Hydroxymethylglutaryl-CoA Reductase Inhibitors